TO THE EDITOR: We would like to appreciate the interest shown in our article by Dr. Joo. Our response to his queries is as follows:

\(1\) The risk factors for prediction of recurrence after endoscopic pneumatic dilatation are young age, male sex, shorter duration of symptoms, low pre-treatment lower esophageal sphincter (LES) pressure and post therapy LES pressure above 10 mmHg. In the present study, the response to pneumatic dilatation was not influenced by sex and age.[@B1] In a retrospective study of 52 patients by Mehta et al[@B2] regarding the response of achalasia to pneumatic dilatation, there was no significant difference with respect to gender but younger age was associated with poor response in the Indian subpopulation. The reason why pneumatic dilatation is less effective in male is not known while Ghoshal et al[@B3] have hypothesized that this might be due to the stronger LES musculature in men.

The previous studies have shown that younger patients had a poor outcome. The Indian sub-population studies by Ghoshal et al[@B4] have shown that age did not affect the outcome of pneumatic dilatation which is similar to our study. The explanation for the worse outcome with young age is unknown.

Post pneumatic dilatation manometry was not done in the present study. In the present study, the statistically insignificant association between age and gender with the outcome may be due to the smaller number of patients in each of the subtypes.[@B1]

\(2\) In our study, the failure of therapy was defined as the persistence of symptoms for 4 weeks after pneumatic dilatation and need for further dilatations. The definition of successful treatment has been described in the methodology of the article.

\(3\) The major finding in our study was that the typing of achalasia predicted the response to pneumatic dilatation. We agree that the number of patients in our study was small. A study by Pandolfino et al[@B5] has shown similar results. A larger prospective study with a large number of patients in each subtype and long-term follow-up is needed to further validate the findings of our study.
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